Evidence map›Paper›PMID 40524461›Full record

ArticleBritish journal of haematology2025

Can we identify individuals at risk to develop multiple myeloma? A machine learning-based predictive model.

Moshe Mittelman, Ariel Israel, Howard S Oster, Michael Leshchinsky, Yatir Ben-Shlomo, Eldad Kepten, Osnat Jarchowsky Dolberg, Ran Balicer, Galit Shaham

Abstract read
In one paragraph

Article in British journal of haematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Moshe MittelmanDepartment of Hematology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.ORCID https://orcid.org/0000-0001-7677-9119
Ariel IsraelLeumit Health Services, Tel Aviv, Israel.
Howard S OsterFaculty of Medicine, Tel Aviv University, Tel Aviv, Israel.ORCID https://orcid.org/0000-0003-1936-4675
Michael LeshchinskyInnovation Division, Clalit Health Services, Clalit Research Institute, Tel Aviv-Yafo, Israel.
Yatir Ben-ShlomoInnovation Division, Clalit Health Services, Clalit Research Institute, Tel Aviv-Yafo, Israel.
Eldad KeptenInnovation Division, Clalit Health Services, Clalit Research Institute, Tel Aviv-Yafo, Israel.
Osnat Jarchowsky DolbergDepartment of Hematology, Meir Medical Center, Kfar Saba, Israel.
Ran BalicerInnovation Division, Clalit Health Services, Clalit Research Institute, Tel Aviv-Yafo, Israel.
Galit ShahamInnovation Division, Clalit Health Services, Clalit Research Institute, Tel Aviv-Yafo, Israel.

Funding

Janssen Pharmaceuticals
6 · The paper itself

Abstract

Multiple myeloma evolves unnoticed over years, and when diagnosed, organ damage is common. Electronic health records (EHR) can help in developing predictive models identifying 'healthy' people at risk. MM patients from Clalit Health Services (2002-2019) were matched with healthy controls. Stage I: EHR from 5 years prior to MM diagnosis were reviewed and >200 parameters were compared (patients vs. controls). Stage II: Establishing xgboost model predicting 5 year risk for MM, with validation. Stage III: A simplified logistic regression model for community, requiring 20 variables (Age; Hb; RBC; MCV; RDW; WBC; neutrophils; lymphocytes; monocytes; basophils; glucose; creatinine; total protein; albumin; calcium; uric acid; bilirubin; HDL-C; LDL-C; triglycerides). EHR from the pre-MM period of 4256 patients were compared to controls. Future MM patients had higher ESR, lower Hb, ANC, neutrophil/lymphocyte ratio, higher globulins and ferritin, more immune deficiencies, MDS and FMF. They took fewer tranquilizers, anti-diabetics and statins. Using labs from future MM (n = 19 129) and controls (n = 382 580, 20:1), a predictive model was developed (ROC AUC = 0.836). The simple LR model provided individual risk prediction for MM within 5 years (AUC = 0.72). Two models with machine learning predict the risk of myeloma in 'healthy' individuals within 5 years. The models can be used in practice.

Indexed as

Machine LearningMultiple MyelomaAdultAgedCase-Control StudiesElectronic Health RecordsFemaleHumansMaleMiddle AgedRisk AssessmentRisk Factorscomputer modellingdisease predictiongradient boostedlogistic regressionmultiple myeloma

Identifiers

PMID40524461
PMCPMC12378918

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.